Absci (ABSI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Voting matters and shareholder proposals
Election of two Class II directors for a three-year term expiring at the 2029 annual meeting or until successors are elected and qualified.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board has nominated Prof Sir Menelas Pangalos, Ph.D., and Daniel Rabinovitsj for election as Class II directors.
Audit committee and external auditor matters
Proposal to ratify Ernst & Young LLP as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Absci
- AI-driven ABS-201 nears pivotal Phase 2 readouts for hair loss and endometriosis in major markets.ABSI
Goldman Sachs 47th Annual Global Healthcare Conference 202619 Jun 2026 - AI-powered platform advances ABS-201 in hair loss and endometriosis, with major data ahead.ABSI
Jefferies Global Healthcare Conference 20264 Jun 2026 - Directors elected and auditor ratified with no shareholder questions or opposition.ABSI
AGM 20264 Jun 2026 - ABS-201 advances with key data ahead, cash runway into 2028, and pipeline expansion.ABSI
Q1 202611 May 2026 - AI-driven platform accelerates antibody drug discovery, advancing ABS-201 for AGA and endometriosis.ABSI
Corporate presentation7 May 2026 - Annual meeting to elect directors, ratify auditor, and highlight clinical and AI platform progress.ABSI
Proxy filing23 Apr 2026 - ABS-201 targets AGA and endometriosis with AI-designed antibodies, aiming for major clinical milestones.ABSI
25th Annual Needham Virtual Healthcare Conference16 Apr 2026 - ABS-201 clinical progress and strong cash reserves support major milestones despite higher net loss.ABSI
Q4 202524 Mar 2026 - AI-driven pipeline targets AGA and endometriosis, with pivotal data and commercialization plans ahead.ABSI
Leerink Global Healthcare Conference 20269 Mar 2026